Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo

Olsen, Elise A.; Whiting, David; Savin, Ronald C.; Rodgers, Anthony; Johnson‐Levonas, Amy O.; Round, Elizabeth; Rotonda, J.; Kaufman, Keith D.

doi:10.1016/j.jaad.2011.10.027

Cited by 40 publications

(23 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients treated with finasteride had more hair growth in vertex and anterior/mid scalp regions than in frontal and temporal hairlines ( p < 0.05), corroborating the findings reported by Olsen et al . Those receiving 5% minoxidil and combination therapy also presented similar trend, although no statistical significance was found ( p > 0.05).…”

Section: Discussionsupporting

confidence: 87%

Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients

Sheng

et al. 2015

Dermatologic Therapy

View full text Add to dashboard Cite

Finasteride at 1 mg/day and 5% topical minoxidil are effective in male androgenetic alopecia (MAGA). However, studies describing their effects in Chinese individuals are scarce. 450 Chinese MAGA patients were randomly assigned to receive finasteride (n = 160), minoxidil (n = 130) and combined medication (n = 160) for 12 months. The patients returned to the clinic every 3 months for efficacy evaluation. And efficacy was evaluated in 428 men at treatment end, including 154, 122, and 152 in the finasteride, 5% minoxidil, and combination groups, respectively. All groups showed similar baseline characteristics, including age at enrollment, and duration and severity of alopecia (p > 0.05). At 12 months, 80.5, 59, and 94.1% men treated with finasteride, 5% minoxidil and the combination therapy showed improvement, respectively. Adverse reactions were rare (finasteride, 1.8%; minoxidil, 6.1%), and disappeared right after drug withdrawal. In conclusion, finasteride is superior to 5% minoxidil, while the combined medication showed the best efficacy.

show abstract

Section: Discussionsupporting

confidence: 87%

Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients

Sheng

et al. 2015

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…[4][5][6][7][8][9][10] Combined use of oral finasteride and topical minoxidil has also shown better therapeutic efficacy during 1-year follow-up, compared to the use of each single treatment. The effectiveness of both drugs in improving the disease has been demonstrated in several well-designed studies.…”

Section: Introductionmentioning

confidence: 99%

“…The effectiveness of both drugs in improving the disease has been demonstrated in several well-designed studies. [4][5][6][7][8][9][10] Combined use of oral finasteride and topical minoxidil has also shown better therapeutic efficacy during 1-year follow-up, compared to the use of each single treatment. 11,12 Long-term treatment with oral finasteride for hair loss is generally well tolerated.…”

Section: Introductionmentioning

confidence: 99%

A randomized, double‐blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia

Suchonwanit

Srisuwanwattana

Chalermroj

et al. 2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Randomized controlled clinical trials of therapies for other dermatological conditions also may include evaluation of patient photographs to assess efficacy. In trials of topical, oral, and laser treatments for hair loss, efficacy has been evaluated through review of standardized baseline and post‐treatment photographs . This global approach to photographic assessment is also used in the study of therapies for scarring and hyperpigmentation .…”

Section: Discussionmentioning

confidence: 99%

Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study

Eichenfield

Rosso²,

Tan

et al. 2019

British Journal of Dermatology

View full text Add to dashboard Cite

SummaryBackgroundOnce‐daily topical oxymetazoline cream 1·0% significantly reduced persistent facial erythema of rosacea in trials requiring live, static patient assessments.ObjectivesTo evaluate critically the methodology of clinical trials that require live, static patient assessments by determining whether assessment of erythema is different when reference to the baseline photograph is allowed.MethodsIn two identically designed, randomized, phase III trials, adults with persistent facial erythema of rosacea applied oxymetazoline or vehicle once daily. This phase IV study evaluated standardized digital facial photographs from the phase III trials to record ≥ 1‐grade Clinician Erythema Assessment (CEA) improvement at 1, 3, 6, 9 and 12 h postdose.ResultsAmong 835 patients (oxymetazoline n = 415, vehicle n = 420), significantly greater proportions of patients treated with oxymetazoline vs. vehicle achieved ≥ 1‐grade CEA improvement. For the comparison between phase IV study results and the original phase III analysis, when reference to baseline photographs was allowed while evaluating post‐treatment photographs, the results for oxymetazoline were similar to results of the phase III trials (up to 85.7%), but a significantly lower proportion of vehicle recipients achieved ≥ 1‐grade CEA improvement (up to 29.7% [phase 4] vs. 52.3% [phase 3]; P<0.001). In the phase IV study, up to 80·2% of patients treated with oxymetazoline achieved at least moderate erythema improvement vs. up to 22·9% of patients treated with vehicle. The association between patients’ satisfaction with facial skin redness and percentage of erythema improvement was statistically significant.ConclusionsAssessment of study photographs, with comparison to baseline, confirmed significant erythema reduction with oxymetazoline on the first day of application. Compared with the phase III trial results, significantly fewer vehicle recipients attained ≥ 1‐grade CEA improvement, suggesting a mitigated vehicle effect. This methodology may improve the accuracy of clinical trials evaluating erythema severity.

show abstract

Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo

Cited by 40 publications

References 12 publications

Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients

Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients

A randomized, double‐blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia

Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study

Contact Info

Product

Resources

About